Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Akihito Kawazoe*, Rui-Hua Xu, Pilar GarcĂ­a-Alfonso, Maria Passhak, Hao-Wei Teng, Ardaman Shergill, Mahmut Gumus, Camilla Qvortrup, Sebastian Stintzing, Kathryn Towns, Tae Won Kim, Kai Keen Shiu, Juan Cundom, Sumitra Ananda, Andrey Lebedinets, Rong Fu, Rishi Jain, David Adelberg, Volker Heinemann, Takayuki YoshinoElena Elez, LEAP-017 Investigators

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science